PHP
APRE icon

Parkman Healthcare Partners’s Aprea Therapeutics APRE Stock Holding History

Parkman Healthcare Partners’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,002
Closed -$482K – 85
2020
Q3 		$482K Sell
1,002
-1,000
-50% -$560K 0.13% 81
2020
Q2 		$1.55M Buy
2,002
+500
+33% +$328K 0.44% 62
2020
Q1 		$1.04M Buy
+1,502
New +$1.1M 0.48% 53

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Parkman Healthcare Partners's APRE Position: Q4 2020 in Review

Parkman Healthcare Partners sold out of Aprea Therapeutics (APRE) in Q4 2020, closing a stake of 1,002 shares — an estimated $482K sold.

Parkman Healthcare Partners first reported a position in APRE in Q1 2020 and held it in 3 quarters. The position peaked at $1.55M in Q2 2020. 66 funds tracked by Wall St. Rank hold APRE as of Q4 2020.

  • Parkman Healthcare Partners reported no remaining Aprea Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 1,002 Aprea Therapeutics shares in Q4 2020, an estimated $482K.
  • Parkman Healthcare Partners first reported a position in Aprea Therapeutics in Q1 2020 and held it in 3 quarters.
  • Parkman Healthcare Partners's Aprea Therapeutics position peaked at $1.55M in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2020.

Based on Parkman Healthcare Partners's 13F filing for Q4 2020, filed 12 Feb 2021.